CIM
VRTX icon

Calvert Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Calvert Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-15,857
Closed -$1.17M – 600
2016
Q4 		$1.17M Buy
15,857
+524
+3% +$42.6K 0.04% 360
2016
Q3 		$1.34M Buy
15,333
+811
+6% +$76.6K 0.05% 342
2016
Q2 		$1.25M Sell
14,522
-438
-3% -$37.8K 0.05% 326
2016
Q1 		$1.19M Buy
14,960
+3,117
+26% +$282K 0.05% 293
2015
Q4 		$1.49M Buy
11,843
+2,734
+30% +$330K 0.07% 237
2015
Q3 		$949K Buy
9,109
+449
+5% +$57.7K 0.05% 230
2015
Q2 		$1.07M Sell
8,660
-2,537
-23% -$320K 0.05% 226
2015
Q1 		$1.32M Buy
11,197
+1,594
+17% +$191K 0.09% 197
2014
Q4 		$1.14M Buy
9,603
+938
+11% +$106K 0.08% 206
2014
Q3 		$973K Buy
8,665
+6,423
+286% +$612K 0.07% 207
2014
Q2 		$212K Buy
+2,242
New +$157K 0.01% 336

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Calvert Investment Management's VRTX Position: Q1 2017 in Review

Calvert Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2017, closing a stake of 15,857 shares — an estimated $1.17M sold.

Calvert Investment Management first reported a position in VRTX in Q2 2014 and held it in 11 quarters. The position peaked at $1.49M in Q4 2015. 522 funds tracked by Wall St. Rank hold VRTX as of Q1 2017.

  • Calvert Investment Management reported no remaining Vertex Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Calvert Investment Management sold 15,857 Vertex Pharmaceuticals shares in Q1 2017, an estimated $1.17M.
  • Calvert Investment Management first reported a position in Vertex Pharmaceuticals in Q2 2014 and held it in 11 quarters.
  • Calvert Investment Management's Vertex Pharmaceuticals position peaked at $1.49M in Q4 2015.
  • 522 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2017.

Based on Calvert Investment Management's 13F filing for Q1 2017.